Baidu
map

β-内酰胺类抗生素/β-内酰胺酶抑制剂复方制剂临床应用专家共识(2020年版)

2020-01-10 中华医学杂志, 2020,100(10) : 738-747.

革兰阴性菌及少数革兰阳性菌对β-内酰胺类抗生素耐药的最重要机制是产生各种β-内酰胺酶。β-内酰胺酶抑制剂能够抑制部分β-内酰胺酶,避免β-内酰胺类抗生

中文标题:

β-内酰胺类抗生素/β-内酰胺酶抑制剂复方制剂临床应用专家共识(2020年版)

发布机构:

发布日期:

2020-01-10

简要介绍:

革兰阴性菌及少数革兰阳性菌对β-内酰胺类抗生素耐药的最重要机制是产生各种β-内酰胺酶。β-内酰胺酶抑制剂能够抑制部分β-内酰胺酶,避免β-内酰胺类抗生素被水解而失活。因此,β-内酰胺类抗生素/β-内酰胺酶抑制剂复方制剂(简称β-内酰胺酶抑制剂复方制剂)是临床治疗产β-内酰胺酶细菌感染的重要选择。我国临床使用的β-内酰胺酶抑制剂复方制剂的种类和规格繁多,临床工作者对该类制剂的特点了解参差不齐,临床不合理使用问题比较突出。本编写小组在2015年编写的《β-内酰胺类抗生素/β-内酰胺酶抑制剂合剂临床应用专家共识》,在指导和规范临床合理使用此类抗菌药物中发挥了重要作用。随着细菌耐药性的变迁及多个新的酶抑制剂复方制剂应用于临床,为了进一步规范β-内酰胺酶抑制剂复方制剂的临床应用,延缓细菌对其耐药性的发生和发展,专家组特对共识进行了更新。

 

下载附件:

(因为版权问题,不支持下载)

评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1201831, encodeId=8117120183197, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce496545404, createdName=ms7000001031705413, createdTime=Fri Mar 11 23:08:54 CST 2022, time=2022-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185746, encodeId=98091185e4650, content=获益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f865475954, createdName=ms3000001627599051, createdTime=Tue Jan 18 20:34:31 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968594, encodeId=60d496859412, content=学习啦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210521/b436ec2680e649b9aab8fe9013f28b89/1c045bfba5b1429cba00b9bf54560d48.jpg, createdBy=c2492570261, createdName=12580979m36暂无昵称, createdTime=Wed May 26 11:50:52 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917592, encodeId=790d91e59269, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJjdkFuFT9DxkzjiaO5tOZlWvxUdRETwQ5UJ0YfHLz4PJtLpWPTfJjwYBRzhz9OXLQAPH9LYibmER8A/132, createdBy=5d2a5176562, createdName=146e9e94m10(暂无昵称), createdTime=Sun Jan 17 23:27:03 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893619, encodeId=bc42893619fb, content=没积分啊 买也不行, beContent=null, objectType=guider, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJtrRoAc3M9Enibgku7THzMZZWRGrEV4PFwguoxiadyrIZBhdf1WeSY76OyFycUPyfic89F8QVRPNnFw/132, createdBy=e9442042687, createdName=wanglu5813977, createdTime=Wed Oct 21 22:35:34 CST 2020, time=2020-10-21, status=1, ipAttribution=)]
    2022-03-11 ms7000001031705413

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1201831, encodeId=8117120183197, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce496545404, createdName=ms7000001031705413, createdTime=Fri Mar 11 23:08:54 CST 2022, time=2022-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185746, encodeId=98091185e4650, content=获益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f865475954, createdName=ms3000001627599051, createdTime=Tue Jan 18 20:34:31 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968594, encodeId=60d496859412, content=学习啦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210521/b436ec2680e649b9aab8fe9013f28b89/1c045bfba5b1429cba00b9bf54560d48.jpg, createdBy=c2492570261, createdName=12580979m36暂无昵称, createdTime=Wed May 26 11:50:52 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917592, encodeId=790d91e59269, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJjdkFuFT9DxkzjiaO5tOZlWvxUdRETwQ5UJ0YfHLz4PJtLpWPTfJjwYBRzhz9OXLQAPH9LYibmER8A/132, createdBy=5d2a5176562, createdName=146e9e94m10(暂无昵称), createdTime=Sun Jan 17 23:27:03 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893619, encodeId=bc42893619fb, content=没积分啊 买也不行, beContent=null, objectType=guider, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJtrRoAc3M9Enibgku7THzMZZWRGrEV4PFwguoxiadyrIZBhdf1WeSY76OyFycUPyfic89F8QVRPNnFw/132, createdBy=e9442042687, createdName=wanglu5813977, createdTime=Wed Oct 21 22:35:34 CST 2020, time=2020-10-21, status=1, ipAttribution=)]
    2022-01-18 ms3000001627599051

    获益匪浅

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1201831, encodeId=8117120183197, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce496545404, createdName=ms7000001031705413, createdTime=Fri Mar 11 23:08:54 CST 2022, time=2022-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185746, encodeId=98091185e4650, content=获益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f865475954, createdName=ms3000001627599051, createdTime=Tue Jan 18 20:34:31 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968594, encodeId=60d496859412, content=学习啦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210521/b436ec2680e649b9aab8fe9013f28b89/1c045bfba5b1429cba00b9bf54560d48.jpg, createdBy=c2492570261, createdName=12580979m36暂无昵称, createdTime=Wed May 26 11:50:52 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917592, encodeId=790d91e59269, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJjdkFuFT9DxkzjiaO5tOZlWvxUdRETwQ5UJ0YfHLz4PJtLpWPTfJjwYBRzhz9OXLQAPH9LYibmER8A/132, createdBy=5d2a5176562, createdName=146e9e94m10(暂无昵称), createdTime=Sun Jan 17 23:27:03 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893619, encodeId=bc42893619fb, content=没积分啊 买也不行, beContent=null, objectType=guider, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJtrRoAc3M9Enibgku7THzMZZWRGrEV4PFwguoxiadyrIZBhdf1WeSY76OyFycUPyfic89F8QVRPNnFw/132, createdBy=e9442042687, createdName=wanglu5813977, createdTime=Wed Oct 21 22:35:34 CST 2020, time=2020-10-21, status=1, ipAttribution=)]
    2021-05-26 12580979m36暂无昵称

    学习啦

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1201831, encodeId=8117120183197, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce496545404, createdName=ms7000001031705413, createdTime=Fri Mar 11 23:08:54 CST 2022, time=2022-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185746, encodeId=98091185e4650, content=获益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f865475954, createdName=ms3000001627599051, createdTime=Tue Jan 18 20:34:31 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968594, encodeId=60d496859412, content=学习啦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210521/b436ec2680e649b9aab8fe9013f28b89/1c045bfba5b1429cba00b9bf54560d48.jpg, createdBy=c2492570261, createdName=12580979m36暂无昵称, createdTime=Wed May 26 11:50:52 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917592, encodeId=790d91e59269, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJjdkFuFT9DxkzjiaO5tOZlWvxUdRETwQ5UJ0YfHLz4PJtLpWPTfJjwYBRzhz9OXLQAPH9LYibmER8A/132, createdBy=5d2a5176562, createdName=146e9e94m10(暂无昵称), createdTime=Sun Jan 17 23:27:03 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893619, encodeId=bc42893619fb, content=没积分啊 买也不行, beContent=null, objectType=guider, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJtrRoAc3M9Enibgku7THzMZZWRGrEV4PFwguoxiadyrIZBhdf1WeSY76OyFycUPyfic89F8QVRPNnFw/132, createdBy=e9442042687, createdName=wanglu5813977, createdTime=Wed Oct 21 22:35:34 CST 2020, time=2020-10-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1201831, encodeId=8117120183197, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce496545404, createdName=ms7000001031705413, createdTime=Fri Mar 11 23:08:54 CST 2022, time=2022-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185746, encodeId=98091185e4650, content=获益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f865475954, createdName=ms3000001627599051, createdTime=Tue Jan 18 20:34:31 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968594, encodeId=60d496859412, content=学习啦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210521/b436ec2680e649b9aab8fe9013f28b89/1c045bfba5b1429cba00b9bf54560d48.jpg, createdBy=c2492570261, createdName=12580979m36暂无昵称, createdTime=Wed May 26 11:50:52 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917592, encodeId=790d91e59269, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJjdkFuFT9DxkzjiaO5tOZlWvxUdRETwQ5UJ0YfHLz4PJtLpWPTfJjwYBRzhz9OXLQAPH9LYibmER8A/132, createdBy=5d2a5176562, createdName=146e9e94m10(暂无昵称), createdTime=Sun Jan 17 23:27:03 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893619, encodeId=bc42893619fb, content=没积分啊 买也不行, beContent=null, objectType=guider, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJtrRoAc3M9Enibgku7THzMZZWRGrEV4PFwguoxiadyrIZBhdf1WeSY76OyFycUPyfic89F8QVRPNnFw/132, createdBy=e9442042687, createdName=wanglu5813977, createdTime=Wed Oct 21 22:35:34 CST 2020, time=2020-10-21, status=1, ipAttribution=)]
    2020-10-21 wanglu5813977

    没积分啊 买也不行

    0

拓展阅读

2010SOGC:产科手术中预防性抗生素的应用

加拿大妇产科医生协会(SOGC,Society of Obstetricians and Gynaecologists of Canada) · 2010-09-01

2010 SIR/CIRSE/ CIRA 成人介入诊疗的抗生素使用指南

介入放射学会(SIR,Society of Interventional Radiology) · 2010-11-01

2011 妇产科抗生素使用指南

中华医学会妇产科学分会 · 2011-03-11

2011 EAST 开放性骨折预防性使用抗生素实践管理指南(更新版)

美国东部创伤外科学会(EAST,The Eastern Association for the Surgery of Trauma) · 2011-03-31

2011-ACOG临床指南120:接生和分娩中预防性使用抗生素

美国妇产科医师学会(ACOG,American College of Obstetricians and Gynecologists) · 2011-06-20

Baidu
map
Baidu
map
Baidu
map